Published in Cancer Weekly, May 10th, 1999
DNA-based immunization is a rapidly expanding area of vaccine research and development. It has enormous potential as an anticancer immunotherapeutic.
Current experimental strategies use recombinant viral vectors or nonviral plasmids. Nonviral plasmid DNA-based immunizations, however, have several clinically relevant advantages over viral vector strategies.
T. Tuting and colleagues from the University of Pittsburgh, Pennsylvania, and the J-Gutenberg University, Germany, characterized and compared the immune...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.